Resource Type

Journal Article 714

Conference Videos 7

Year

2024 3

2023 39

2022 68

2021 62

2020 46

2019 69

2018 42

2017 42

2016 32

2015 42

2014 43

2013 37

2012 21

2011 29

2010 22

2009 32

2008 20

2007 20

2006 8

2005 2

open ︾

Keywords

fuel cell 13

immunotherapy 8

prognosis 8

B-spline 7

acute myeloid leukemia 7

acute promyelocytic leukemia 7

COVID-19 6

solar cell 6

biomarker 5

hematopoietic stem cell transplantation 5

hepatocellular carcinoma 5

hydrogen energy 5

stem cell 5

acute lymphoblastic leukemia 4

cell proliferation 4

control 4

hepatitis B virus 4

lung cancer 4

microbial fuel cell 4

open ︾

Search scope:

排序： Display mode:

characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cellacute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia

Frontiers of Medicine 2022, Volume 16, Issue 1,   Pages 139-149 doi: 10.1007/s11684-021-0835-8

Abstract: The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients withrelapsed/refractory B-cell precursor acute lymphoblastic leukemia.and A-2019 are potent antitumor agents and capable of recruiting CD3 positive T cells, enhancing T-cellfunction, mediating B-cell depletion, and eventually inhibiting tumor growth in Raji xenograft models

Keywords： B-cell acute lymphoblastic leukemia     bispecific antibody     trispecific antibody     CD19     CD20    

HTML PDF Collect

Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia

Jianfeng Li, Yuting Dai, Liang Wu, Ming Zhang, Wen Ouyang, Jinyan Huang, Saijuan Chen

Frontiers of Medicine 2021, Volume 15, Issue 3,   Pages 347-371 doi: 10.1007/s11684-020-0821-6

Abstract: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by genetic alterations withinhibitors (e.g., imatinib), immunomodulators, monoclonal antibodies, and chimeric antigen receptor T-cell

Keywords： BCP-ALL     subtypes     translocation     aneuploidy     sequence mutations    

HTML PDF Collect

Comprehensive treatment of acute-on-chronic liver failure in a patient with hepatitis B: a case report

Lei Li,Yimei Liu,Tiancheng Luo,Jian Zhou,Yingyong Hou,Xizhong Shen,Jiyao Wang

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 250-253 doi: 10.1007/s11684-014-0333-3

Abstract:

The clinical data of a patient with acute-on-chronic liver failure were analyzed retrospectively.The patient has suffered from hepatitis B for 30 years.Comprehensive treatments included effective inhibition of hepatitis B virus replication and intensive

Keywords： acute-on-chronic liver failure     submassive necrosis     viral hepatitis B     esophageal variceal bleeding     liver    

HTML PDF Collect

Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal ResidualDisease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation Article

Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang

Engineering 2019, Volume 5, Issue 1,   Pages 150-155 doi: 10.1016/j.eng.2018.12.006

Abstract: Leukemia relapse is still the leading cause of treatment failure after allogeneic hematopoietic stem celltransplantation (allo-HSCT) for B cell acute lymphoblastic leukemia (B-ALL).residual disease (MRD) is predictive of forthcoming hematological relapse after hematopoietic stem cellNo patient developed acute graft-versus-host disease (aGVHD), and no patient died of cytokine releasein B-ALL after allo-HSCT and for those who were not responsive to DLI.

Keywords： Donor-derived CD19-targeted T cell infusion     Hematopoietic stem cell transplantation     B cell acute lymphoblastic    

HTML PDF Collect

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 442-458 doi: 10.1007/s11684-021-0877-y

Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is one of the most dangerous hematological malignancies,We found that chidamide, an HDAC inhibitor, exerts an antitumor effect on T-ALL cell lines and primary

Keywords： T-cell acute lymphoblastic leukemia     HDAC inhibitor     chidamide     NOTCH1     MYC     ubiquitination    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAcute myeloid leukemia (AML) is a group of heterogeneous myeloid malignancies.Allogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemia

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Aldolase B attenuates clear cell renal cell carcinoma progression by inhibiting CtBP2

Frontiers of Medicine 2023, Volume 17, Issue 3,   Pages 503-517 doi: 10.1007/s11684-022-0947-9

Abstract: Aldolase B (ALDOB), a glycolytic enzyme, is uniformly depleted in clear cell renal cell carcinoma (ccRCCALDOB inhibited CtBP2-mediated repression of multiple cell cycle inhibitor, proapoptotic, and epithelial

Keywords： ALDOB     kidney cancer     cell proliferation    

HTML PDF Collect

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 783-804 doi: 10.1007/s11684-021-0904-z

Abstract: Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematologicalIn this review, through a representative case study, we summarize the current experience of CAR T-cellthe causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell

Keywords： CAR T cells     hematological malignancies     review    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some contemporary clinicaland other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cellprecursor, immature T-cell, -rearranged, Ph-positive and -positive ALL, that may respond to BCL-2targetable genetic lesions, current approaches that offer hope include blinatumomab, inotuzumab and CAR-T celltherapy for B-ALL, and daratumumab and nelarabine for T-ALL.

Keywords： acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy     CAR T-cell therapy    

HTML PDF Collect

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 815-826 doi: 10.1007/s11684-021-0891-0

Abstract: Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL)

Keywords： B-cell lymphoma     oral drug     targeted therapy     immunotherapy     COVID-19 pandemic    

HTML PDF Collect

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Frontiers of Medicine 2012, Volume 6, Issue 4,   Pages 416-420 doi: 10.1007/s11684-012-0224-4

Abstract:

Acute lymphoblastic leukemia includes T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acutelymphoblastic leukemia (B-ALL).In children, T-ALL usually has a worse prognosis than B-ALL, although childhood T-ALL prognoses haveThis novel subtype of T-ALL was called early T-cell precursor acute lymphoblastic leukemia (ETP-ALL).Our findings demonstrate that early T-cell precursor leukemia is a very high-risk subtype of acute lymphoblastic

Keywords： acute lymphoblastic leukemia     early T precursor     prognosis    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellCAR bearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cellTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatment

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 747-757 doi: 10.1007/s11684-022-0954-x

Abstract: efficacy of inactivated vaccination in neutralization against emerging variants and antigen-specific Bcell response.Similarly, the responses of SARS-CoV-2 RBD-specific B cells and memory B cells were boosted by the secondor two doses), which enhanced neutralization against highly mutated SARS-CoV-2 variants and memory Bcell responses.

Keywords： COVID-19 convalescent     SARS-CoV-2     inactivated vaccination     neutralizing antibody     B cell response    

HTML PDF Collect

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50% long-term complete response in relapsed or refractory diffuse large B-cell lymphoma (DLBCLHowever, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cellSingle-cell RNA sequencing results were obtained from core needle biopsy tumor samples collected fromImmunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansion

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

Study of recombinant human IFN-α-2b bacilli Calmette–Guerin activated killer cells and against bladdercancer cell in vitro

FAN Xiaodong, HAN Ruifa

Frontiers of Medicine 2007, Volume 1, Issue 4,   Pages 377-380 doi: 10.1007/s11684-007-0073-8

Abstract: Recombinant IFN--2b-BCG, wild-type BCG (wBCG), wild-type BCG and IFN--2b were coincubated with PBMCs

Keywords： Urology     powerful     2b-BCG     Tianjin institute     wild-type    

HTML PDF Collect

Title Author Date Type Operation

characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cellacute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia

Journal Article

Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia

Jianfeng Li, Yuting Dai, Liang Wu, Ming Zhang, Wen Ouyang, Jinyan Huang, Saijuan Chen

Journal Article

Comprehensive treatment of acute-on-chronic liver failure in a patient with hepatitis B: a case report

Lei Li,Yimei Liu,Tiancheng Luo,Jian Zhou,Yingyong Hou,Xizhong Shen,Jiyao Wang

Journal Article

Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal ResidualDisease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation

Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang

Journal Article

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Aldolase B attenuates clear cell renal cell carcinoma progression by inhibiting CtBP2

Journal Article

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Journal Article

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Journal Article

Study of recombinant human IFN-α-2b bacilli Calmette–Guerin activated killer cells and against bladdercancer cell in vitro

FAN Xiaodong, HAN Ruifa

Journal Article